Arcutis Biotherapeutics (ARQT) Gets a Buy Rating from Mizuho Securities

In a report released today, Uy Ear from Mizuho Securities reiterated a Buy rating on Arcutis Biotherapeutics (ARQTResearch Report), with a price target of $57.00. The company’s shares closed last Tuesday at $21.51.

Ear has an average return of 14.5% when recommending Arcutis Biotherapeutics.

According to TipRanks.com, Ear is ranked #7045 out of 7897 analysts.

Currently, the analyst consensus on Arcutis Biotherapeutics is a Strong Buy with an average price target of $47.00, representing a 124.0% upside. In a report issued on May 10, Morgan Stanley also maintained a Buy rating on the stock with a $36.00 price target.

See the top stocks recommended by analysts >>

Arcutis Biotherapeutics’ market cap is currently $1.1B and has a P/E ratio of -4.56.

Based on the recent corporate insider activity of 49 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ARQT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Arcutis Biotherapeutics, Inc. engages in the development and commercialization of treatments for dermatological diseases. Its piepline consists of topical treatments for plaque psoriasis, atopic dermatitis, eczema, vitiligo, alopecia areata, and seborrheic dermatitis. The company was founded by Bhaskar Chaudhuri and David W. Osborne on June 1, 2016 and is headquartered in Westlake Village, CA.

Read More on ARQT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed